These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9819761)

  • 1. In vitro cytotoxicity of recombinant human-TNF-alpha and actinomycin D on canine normal and tumor cells.
    Aoki M; Kuwamura M; Kotani T; Katamoto H; Kubo K; Nomura K; Sasaki N; Ohashi F
    J Vet Med Sci; 1998 Oct; 60(10):1087-91. PubMed ID: 9819761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity induced by recombinant human tumor necrosis factor-alpha dependent on the types of its receptors on canine cells.
    Aoki M; Sasaki N; Nomura K; Katamoto H; Kubo K; Kodama H; Mukamoto M; Shimada T; Ohashi F
    J Vet Med Sci; 1998 Aug; 60(8):889-95. PubMed ID: 9764400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results.
    Lasek W; Giermasz A; Kuc K; Wańkowicz A; Feleszko W; Gołab J; Zagozdzon R; Stokłosa T; Jakóbisiak M
    Int J Cancer; 1996 May; 66(3):374-9. PubMed ID: 8621260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of antitumor efficacy by the combination of actinomycin D with tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice.
    Lasek W; Wańkowicz A; Kuc K; Feleszko W; Giermasz A; Jakóbisiak M
    Oncology; 1996; 53(1):31-7. PubMed ID: 8570128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of cytotoxicity of cisplatin in vitro by recombinant human tumor necrosis factor and/or recombinant human interferon-alpha, -beta and -gamma.
    Kim CM; Hong WS; Lee JO; Kang TW; Kim YW; Song JK; Yun TK; Kim CY
    Jpn J Cancer Res; 1989 Sep; 80(9):904-9. PubMed ID: 2513306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic cytotoxicity of recombinant human TNF and various anti-cancer drugs.
    Watanabe N; Niitsu Y; Yamauchi N; Ohtsuka Y; Sone H; Neda H; Maeda M; Urushizaki I
    Immunopharmacol Immunotoxicol; 1988; 10(1):117-27. PubMed ID: 2452179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells.
    Matsuzaki H; Schmied BM; Ulrich A; Standop J; Schneider MB; Batra SK; Picha KS; Pour PM
    Clin Cancer Res; 2001 Feb; 7(2):407-14. PubMed ID: 11234897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF induces cytoplasmic vesicles in actinomycin D-treated K 562 cells.
    Munker R; Greither L; Darsow M; Pander S; Wilmanns W
    Ann Hematol; 1992 Jul; 65(1):50-2. PubMed ID: 1643161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) in a mouse bladder tumor (MBT-2).
    Bahnson RR; Ratliff TL
    J Urol; 1990 Jul; 144(1):172-5. PubMed ID: 2113589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of recombinant tumor necrosis factor on HL-60 cells: cell-cycle specificity and synergism with actinomycin D.
    Darzynkiewicz Z; Carter SP; Old LJ
    J Cell Physiol; 1987 Mar; 130(3):328-35. PubMed ID: 3470296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D.
    Mori S; Murakami-Mori K; Nakamura S; Ashkenazi A; Bonavida B
    J Immunol; 1999 May; 162(9):5616-23. PubMed ID: 10228045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP; Zisman A; Bonavida B
    Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tumour necrosis factor-alpha (TNF-alpha) sensitive adherent KYM-1D4 derived cell line: use in TNF-alpha cytotoxicity assays in the presence of actinomycin D.
    Meager A
    J Immunol Methods; 1999 Jul; 227(1-2):197-8. PubMed ID: 10485267
    [No Abstract]   [Full Text] [Related]  

  • 14. Modulation of P-glycoprotein-mediated doxorubicin resistance in canine cell lines.
    Page RL; Hughes CS; Huyan S; Sagris J; Trogdon M
    Anticancer Res; 2000; 20(5B):3533-8. PubMed ID: 11131658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule-dependent enhanced lethality with combined administration of actinomycin D and tumor necrosis factor in mice.
    Buckley NJ; Walther PJ; Das AK; Poulton SH
    J Biol Response Mod; 1989 Jun; 8(3):287-96. PubMed ID: 2746299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity.
    Ziegler-Heitbrock HW; Möller A; Linke RP; Haas JG; Rieber EP; Riethmüller G
    Cancer Res; 1986 Nov; 46(11):5947-52. PubMed ID: 3756932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor and chemotherapeutic agents. Potentiation of cytotoxicity with interferon gamma.
    Dawson DE; Gapany M; Burgess RC; Boesen PV; Headley DB
    Arch Otolaryngol Head Neck Surg; 1992 Nov; 118(11):1168-71. PubMed ID: 1418895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor and cytotoxic agents. Effect on squamous carcinoma lines.
    Gapany M; Dawson DE; Schriever C; Burgess R; Gipple JR; Riggs CE
    Arch Otolaryngol Head Neck Surg; 1990 Apr; 116(4):436-9. PubMed ID: 2317326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of recombinant human tumor necrosis factor-alpha (rH-TNF alpha) and liposome-entrapped rH-TNF alpha.
    Wakabayashi T; Yoshida J; Ishiyama J; Mizuno M
    Neurol Med Chir (Tokyo); 1997 Oct; 37(10):739-45; discussion 745-6. PubMed ID: 9362133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines.
    Fransen L; Van der Heyden J; Ruysschaert R; Fiers W
    Eur J Cancer Clin Oncol; 1986 Apr; 22(4):419-26. PubMed ID: 3089802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.